Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WA | N.MMED.WR | N.MMED.WS | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc > Sell sell sell

<< Previous

Bullboard Posts

Next >>

Comment by Superss63on Apr 27, 2021 5:45pm

333 Views

Post# 33079266

RE:Sell sell sell

I would not call it disappointing, I would call it expected. Normal after the announcement & run up. Wait a few weeks to see where it will really settle. Congrats on cashing out at $5.90. I thought of selling 1/4 but had set a sell order a little too high. C'est la vie.

<< Previous

Bullboard Posts

Next >>

How a junior advances one of the largest undeveloped diamond projects